Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNAM.C. Liu, David R. Spigel, Geoffrey R. Oxnard et al.|Annals of Oncology|2020Cited by 1.5k
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 studyJosep Tabernero, Federico Nasroulah, Sara Lonardi et al.|The Lancet Oncology|2015Cited by 954
Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE StudyHoward S. Höchster, Eric Hedrick, Lowell L. Hart et al.|Journal of Clinical Oncology|2008Cited by 623
Evaluation of cell-free DNA approaches for multi-cancer early detectionArash Jamshidi, Charles Swanton, Minetta C. Liu et al.|Cancer Cell|2022Cited by 311
Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trialShalini Makawita, Milind Javle, Ghassan K. Abou‐Alfa et al.|Future Oncology|2020Cited by 91